NIH Funds Research on Biofusionary Tissue Sealing Technology to Prevent Post-Surgical Leaks

Share Article

Tissue sealing technology to reduce lung surgery complications is the focus of a NIH grant awarded to Rocky Mountain Biosystems, Inc. Each year, thousands of Americans have complications caused by dangerous air leaks following lung resection surgery. NIH has awarded a grant to Rocky Mountain Biosystems, Inc. to advance research in applying their Biofusionary® tissue sealing technology to eliminate air leak complications with a uniform, effective tissue seal.

Rocky Mountain Biosystems, Inc.® (RMBI®), a Denver area biotechnology company, announced that it received a Phase I - Small Business Innovation Research grant (SBIR) for $131,658 from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The grant will advance RMBI's Biofusionary® Systems tissue sealing technology to effectively seal lung tissue and prevent air leaks -- a serious complication in up to half of all lung resection surgeries.

Lung disease, including lung cancer and chronic obstructive pulmonary disease (COPD), is America's number three killer, responsible for one in every seven deaths. In the U.S., over 200,000 lung resection surgeries are performed each year to provide the best opportunity for improving life and lengthening survival for patients suffering from lung disease. The number of these surgeries is expected to double by the end of the decade. RMBI's Biofusionary technology is designed to eliminate air leaks -- one of the most common and dangerous complications. Currently, these complications extend a patient's hospital stay, generate an additional average cost of $40,000-$60,000 per hospitalization and increase the overall death rate.

"Our experiments suggest that our proprietary activated adhesive will be useful for wound closure following lung surgery, as well as other types of tissue sealing. It produces a uniform, fluid and air tight seal in seconds. We've designed it for use in both internal and external procedures," said Kevin Marchitto, RMBI's CEO.

During the study, RMBI will adapt and test its innovative activated sealing system with a prototype applicator and energy source. The Biofusionary Systems technology involves non-contact activation of a specially formulated adhesive to bond and secure tissue. RMBI's technology builds on years of research and product development in the field of electromagnetic tissue interactions by the Principal Investigator, Dr. Kevin Marchitto, and co-investigator, Dr. Stephen Flock.

The tissue sealing market is estimated at over $1 billion annually. RMBI has now received five NIH grants to research various innovative applications of their technology.

Biofusionary Systems' tissue sealing products are being developed at Rocky Mountain Biosystems, Inc. (RMBI), a five-year-old biotechnology company located in the Denver metropolitan area. RMBI blends physics and biology to improve medical outcomes through advanced tissue sealing and transdermal drug delivery products. The Biofusionary Systems tissue sealing technology provides a strong, uniform tissue seal in fluid and pressure environments and is designed to achieve better therapeutic outcomes. RMBI is also developing drug delivery devices for improved absorption of drugs and vaccines through the skin.

For more information, or a RMBI interview contact:

Rae Reynolds, Rocky Mountain Biosystems, Inc.



Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rae Reynolds
Email >